EARLY NIVOLUMAB ADDITION TO REGORAFENIB IN PATIENTS WITH HEPATOCELLULAR CARCINOMA PROGRESSING UNDER 1ST LINE THERAPY (GOING TRIAL). INTERIM ANALYSIS AND SAFETY PROFILE

Marco Sanduzzi Zamparelli  ¹     Ana Matilla  ²     José Luis Lledo  ³     Sergio Muñoz-Martínez     Maria Varela  ⁴     Mercedes Iñarrairaegui  ⁵     Christie Perelló  ⁶     Beatriz Mínguez Rodríguez  ⁷     Neus Llarch     laura marquez  ⁸     Antonio Guerrero     Gemma Iserte     Andrés Castaño-García  ⁹     Laura Carrión     Jordi Rimola  ¹⁰     Ángeles García-Criado     Gema Domenech  ¹¹     Loreto Boix     Jordi Bruix     Maria Reig    
¹ BCLC group. Liver Unit, Hospital Clinic of Barcelona, IDIBAPS. CIBERehd, University of Barcelona, Barcelona, Spain
² Gastroenterology Department, Hospital General Universitario Gregorio Marañón, CIBERehd, Madrid, Spain
³ Gastroenterology & Hepatology Department, Hospital Universitario Ramón y Cajal, CIBERehd, Madrid
⁴ Hospital Universitario Central de Asturias, Oviedo, Spain
⁵ Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra IDISNA and CIBEREHD, Navarra, Spain
⁶ Gastroenterology Department. Hepatology Unit, Hospital Universitario Puerta de Hierro, IDIPHISA, CIBERehd, Madrid, Spain
⁷ Liver Unit, Hospital Universitari Vall d'Hebron, Liver Diseases Research Group, Vall d'Hebron Institute of Research (VHIR), Vall d'Hebron Barcelona Hospital Campus. CIBERehd, Universitat Autònoma de B
⁸ Gastroenterology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
⁹ Liver Unit, Gastroenterology Department, Hospital Universitario Central de Asturias, IUOPA, FINBA, Oviedo, Spain
¹⁰ BCLC Group, Radiology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
¹¹ Medical Statistics Core Facility, IDIBAPS-Hospital Clínic, Barcelona, Spain, Barcelona, Spain

Topic
Hepatobiliary, Histopathology

Session
Immune checkpoints in liver disease

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)